CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Kabir Nath

Chief Executive Officer, Compass Pathways

Search every verified Kabir Nath interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Kabir Nath, Chief Executive Officer of Compass Pathways, has been discussing the company's late-stage clinical trials for COMP360, a proprietary synthetic formulation of psilocybin, in the treatment of treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). In interviews, Nath stated that results from two Phase 3 studies showed clinically meaningful responses for a significant percentage of patients after one or two administrations, and he described the company's discussions with the FDA regarding a potential submission for approval. He also commented on a 2026 executive order from President Donald Trump directing the FDA to expedite research and access for psychedelics, saying the company welcomed the order as a move that could accelerate the path to patients while emphasizing the importance of rigorous science. Nath has also addressed topics related to patient access and commercialization. He stated that the company is preparing for a potential commercial launch from the end of 2026, though he said it was premature to discuss pricing. He discussed the importance of working with insurers and government programs to ensure broad and equitable access, and noted the company's early work on reimbursement infrastructure, including a CPT III code for the therapy. In earlier appearances, Nath discussed his background in the biopharmaceutical industry, including prior leadership roles at Otsuka Pharmaceutical, and his personal motivations for working in mental health, citing the suicides of a close friend and his father.

Recent appearances

  • Psilocybin for Treatment Resistent Depression with Kabir Nath | POP 1392

    July 09, 2026 · 📺 Practice of the Practice

    What happens when traditional depression treatments stop working? Could a single psychedelic-assisted therapy session create lasting change? What does the latest research reveal about psilocybin's potential in mental healthcare? In this episode, Joe Sanok speaks with Compass Pathways CEO Kabir Nath about the emerging role of psilocybin-assisted therapy in treating treatment-resistant depression (TRD). They discuss the latest clinical research, how psychedelic therapy is being studied, and its potential to transform mental healthcare.

    Watch on YouTube ↗

  • Compass Pathways CEO on Trump's Order to Expand Psychedelics Research

    April 20, 2026 · 📺 Bloomberg Podcasts

    Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shorteni…

    Watch on YouTube ↗

  • The Future of Psychedelic Medicine | Interview with Compass Pathways CEO Kabir Nath

    March 09, 2026 · 📺 Progress, Potential, and Possibilities

    Kabir Nath is Chief Executive Officer of Compass Pathways ‪@compasspathways‬ ( https://compasspathways.com/ ), a biotechnology company pioneering evidence-based psychedelic innovation for serious mental health conditions. Kabir brings nearly three decades of leadership experience across the biopharmaceutical and medical device industries. Before joining Compass, he served as Senior Managing Director of Global Pharmaceuticals at Otsuka Pharmaceutical Co., and previously as President and CEO of Otsuka’s North America Pharmaceutical Business, where he led the development of therapies and digita…

    Watch on YouTube ↗

  • Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

    December 04, 2025 · 📺 Bloomberg Podcasts

    Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting growth up towards $7 billion by the year 2032. One pharmaceutical company, Compass Pathways, has begun final stage studies aimed at using psilocybin for the treatment of patients with depression. CEO Kabir Nath joined Carol Massar and Alexis Christoforous on 'Bloomberg Businessweek Daily' to discuss commercial viability for psilocybin and the future of the psychedelic drug development market. -------- Watch Bloomberg Radio LIVE on YouTube Weekdays 7am-6pm ET WA…

    Watch on YouTube ↗

  • Advancing Innovation in Mental Health | Kabir Nath, CEO of Compass Pathways

    September 04, 2025 · 📺 Psychedelic Vantage

    Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Their first major initiative is developing COMP360 psilocybin as a potentially differentiated treatment option for those living with TRD, through rigorous scientific research. In this episode, Jake speaks with Kabir Nath, CEO of Compass Pathways, about this important work. Topics covered include: • Kabir’s background and how he came to Compass. • The mission of Compass Pathways. • What treatment-resistant depression is, and Kabir’s interesting perspective on th…

    Watch on YouTube ↗

  • Compass Pathways: Independent Media Talks Psychedelic Medicine

    August 21, 2025 · 📺 Divergent States

    In this episode of Divergent States, we sit down with Kabir Nath, CEO of Compass Pathways, and Dr. Steve Levine, Chief Patient Officer, to talk about the future of psychedelic medicine. From FDA approval and insurance coverage to patient access, cultural safety, and patents, we dig into whether Compass is truly disrupting the pharma model or just reinventing it. We also share a major community update: the official Divergent States Discord is now open to all of r/Psychonaut. Built by Brady and the mod team, the server is a space for harm reduction, trip reports, deep dives, and authentic conn…

    Watch on YouTube ↗

  • Breaking New Ground in Mental Health: Kabir Nath’s Role in Biotech Innovation at Compass Pathways

    August 06, 2024 · 📺 Heidrick & Struggles

    What are the essential qualities required to lead an innovative biotechnology company at the forefront of the psychedelic space? In this episode of The Heidrick & Struggles Leadership Podcast, Heidrick & Struggles’ Charlie Moore speaks to Kabir Nath, CEO of Compass Pathways. Compass Pathways is a company dedicated to studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder, and anorexia. Today, Kabir highlights the paradigm shift in mental health treatment through psychedelics and the challenges of leading a biotech firm in a field n…

    Watch on YouTube ↗

  • 1 Year In Psychedelics With COMPASS Pathaways' ($CMPS) CEO, Kabir Nath

    September 18, 2023 · 📺 Benzinga Partner Studio

    One year into Kabir Nath’s leadership, COMPASS Pathways’ phase 3 trial for innovative treatment resistant depression is progressing. COMPASS Pathways (NASDAQ: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. https://compasspathways.com/   / compass-pathways      / @compasspathways  

    Watch on YouTube ↗

  • Learn More About CPT Codes! In This Interview With Kabir Nath And Steve Levine From COMPASS Pathways

    July 24, 2023 · 📺 Benzinga Partner Studio

    Kabir Nath, CEO and Steve Levine, SVP Patient Access and Medical Affairs tell us what the new CPT III code is and why it is important. COMPASS Pathways (NASDAQ: CMPS) is a mental health care company. Dedicated to accelerating patient access to evidence-based innovation in mental health. https://compasspathways.com/   / compass-pathways      / @compasspathways  

    Watch on YouTube ↗

  • 2020 CNS Summit Keynote Conversation with Kabir Nath

    November 06, 2020 · 📺 Otsuka US

    Kabir Nath, President & CEO, Otsuka North America Pharmaceutical Business discusses Otsuka's commitment to mental health and the various ways Otsuka is broadly engaged in bringing solutions to patients living with mental illness. He speaks on investment in novel solutions including digital therapeutics, as well as the organization's efforts to destigmatize mental illness.

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →